Key result
Direct TGF-beta(1) inhibition, NAPDH oxidase inhibitors, growth factors, and hormonal treatments may significantly reduce cardiac fibrosis after injury as alternatives to angiotensin II blockade.
Why the study?
Do therapies targeting TGF-beta 1 reduce cardiac fibrosis after injury compared to angiotensin II blockade alone?
Do therapies targeting TGF-beta 1 reduce cardiac fibrosis after injury compared to angiotensin II blockade alone?
Answers are grounded in this paper and cite their sources.
This review highlights emerging therapies targeting TGF-beta 1 as potential alternatives or adjuncts to angiotensin II blockade for preventing post-injury cardiac fibrosis.
After injury, the heart undergoes a remodeling process consisting primarily of myocyte hypertrophy, apoptosis and interstitial fibrosis. Although initially beneficial, excess fibrosis gradually results in alteration of left ventricular properties and cardiac dysfunction. Transforming growth factor-beta 1 (TGF-beta(1)) is thought to be a primary mediator of fibrosis within the heart after injury. Currently, angiotensin II blockade is used to inhibit the actions of TGF-beta(1). However, recent studies indicate that angiotensin II blockade alone may not be sufficient to prevent TGF-beta(1)-induced fibrosis. Thus far, both in vivo and in vitro models have shown that direct TGF-beta(1) inhibition, NAPDH oxidase inhibitors, growth factors and hormonal treatment regimens targeting TGF-beta(1) may significantly reduce cardiac fibrosis after injury. This study attempts to underline these alternatives to angiotensin II blockade in combating TGF-beta(1)-induced cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Razi Khan (2007) conducted a review in Myocardial Fibrosis. Therapies targeting TGF-beta(1) vs. Angiotensin II blockade was evaluated on Cardiac fibrosis. Direct TGF-beta(1) inhibition, NAPDH oxidase inhibitors, growth factors, and hormonal treatments may significantly reduce cardiac fibrosis after injury as alternatives to angiotensin II blockade.
Synapse has enriched 10 related papers. Consider them for comparative context: